Greil, R. Rischin, D. Harrington, K. J. Soulieres, D. and Tahara, M. de Castro, G. Psyrri, A. Baste, N. Neupane, P. Bratland, A. Fuereder, T. Hughes, B. G. M. Mesia, Sr., R. Ngamphaiboon, N. Rordorf, T. Ishak, W. Z. Wan and Lin, J. Swaby, R. F. Gumuscu, B. Burtness, B., Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or
with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L)
therapy for recurrent/metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC), Annals of Oncology, (31), S660-S661, 2020, Elsevier, 0923-7534, 1569-8041